You are here:
Vanderbilt Biostatistics Wiki
>
Main Web
>
Seminars
>
WednesdaySeminarSeries
>
PeterGilbert20200930
(14 Sep 2020,
AndrewSpieker
)
(raw view)
E
dit
A
ttach
%HEAD{ NAME="Peter Gilbert, !PhD" AFFILIATION="Fred Hutchinson Cancer Research Center" TITLE="Assessing Immunological Biomarker Surrogate Endpoints in COVID-19 Vaccine Efficacy Trials" IMAGELINK="https://www.fredhutch.org/content/dam/www/faculty-photos/G/peter-gilbert/peter-gilbert.jpg" }% An objective of phase 3 preventive COVID-19 vaccine efficacy trials is to assess immunological biomarkers measured post-vaccination as surrogate endpoints that can constitute the basis for traditional or accelerated approval for the tested vaccine and for other vaccines in the same class. Evidence supporting reliable use of biomarkers for such approval approaches may be based on a synthesis of results from a variety of types of statistical analyses of phase 3 trial data, combined with external data on evidence for biomarkers as mechanisms of protection (e.g., from vaccine challenge studies in animals, from passive antibody transfer challenge studies in animals or humans, and from passive antibody transfer phase 3 trials). In this talk I will summarize current thinking of COVID-19 Prevention Trials Network statisticians on statistical methodological approaches for evaluating the validity of candidate surrogate endpoints from phase 3 trial data. Issues addressed include immunological biomarker sampling design, immunological biomarker selection and optimization, methods for combining biomarkers to develop best predictors of study outcomes, principal stratification approaches to assessing vaccine efficacy moderation, causal mediation approaches to assessing the proportion of vaccine efficacy mediated through one or more biomarkers, a causal intervention approach that addresses how much outcome risk would be altered by stochastically shifting the biomarker distribution upwards, and meta-analysis of a set of phase 3 trials. %TAIL{DATE="30 September 2020"}% <!-- * Set HEAD = <div class="w3-card-2" id="task" style="max-width:750px; margin-left: 0px;"> <header class="w3-container w3-blue" style="padding:40px"><h1>Biostatistics Weekly Seminar</h1><br><h2 style="color:white;">%TITLE%<br><br>%NAME%<br>%AFFILIATION%</h2></header><div class="w3-container" style="padding:40px"><IMG SRC=%IMAGELINK% align="left" id="mug"/> * Set TAIL = <br><h3>Zoom (Link to Follow)<br>%DATE%<br>1:30pm</h3></div></div><br>[[%TOPIC%Itinerary][Speaker Itinerary]] --> <style> .w3-card-2,.w3-example{box-shadow:0 2px 4px 0 rgba(0,0,0,0.16),0 2px 10px 0 rgba(0,0,0,0.12)!important} .w3-blue,.w3-hover-blue:hover{color:#fff!important;background-color:#2196F3!important} .w3-container{padding:0.01em 16px} .foswikiTopic {font-family: 'Open Sans', sans-serif;} /* Removes location hierarchy (usually written in grey text) */ .patternHomePath {display:none;} /* Removes bar with edit and attach buttons and location hierarchy */ .patternTop{display:none;} h1, h2, h3, h4, h5, h6{font-family: 'Montserrat','Open Sans', sans-serif;font-weight:700;} h1, h2, h3, h4, h5, h6{color:#bf1735;} h1:first-of-type{color:#2a3e6e;margin-bottom:25px;margin-top:5px;} .foswikiImage{margin-left:-9px;} img#mug{padding-right: 40px; padding-bottom:25px; height:250px;} </style>
E
dit
|
A
ttach
|
P
rint version
|
H
istory
: r1
|
B
acklinks
|
V
iew topic
|
Edit
w
iki text
|
M
ore topic actions
Topic revision: r1 - 14 Sep 2020,
AndrewSpieker
Main
Department Home Page
Biostatistics Graduate Program
Vanderbilt University Medical Center
Main Web
Main Web Home
Search
Recent Changes
Changes
Topic list
Biostatistics Webs
Archive
Main
Sandbox
System
Register
|
Log In
Copyright © 2013-2022 by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Vanderbilt Biostatistics Wiki?
Send feedback